跳至主要内容
临床试验/NCT00498667
NCT00498667撤回不适用

Evaluation of the Prognostic Value of Early Interim PET/CT for Prediction of Progression Free Survival of Patients With Aggressive B Cells Non Hodgkin Lymphoma

Rambam Health Care Campus1 个研究点 分布在 1 个国家开始时间: 2006年12月最近更新:
适应症

试验速览

阶段
不适用
状态
撤回
试验地点
1
主要终点
progression free survival

研究概览

简要总结

A retrospective analysis will be performed regarding the usefulness of PET/CT performed following 2 cycle of chemotherapy in evaluation of progression, free survival and overall survival of patients with aggressive non Hodgkin Lymphoma.

详细描述

Patients who were treated for aggressive non-Hodgkin lymphoma with adriamycin containing regimen, CHOP and High dose CHOP with or without rituximab were evaluated post 2 cycles of chemotherapy to rule out disease progression . Currently a retrospective evaluation of PET/CT as a predictive value for progression free survival and overall survival is evaluated

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Retrospective

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • aggressive non-Hodgkin lymphoma b cells
  • age 18-70
  • bilirubin less then 2
  • creatinine less then 2
  • Pet/CT performed post 2 cycles

排除标准

  • no PET/CT post 2 cycles performed
  • bilirubin >2
  • creatinine more then 2
  • HIV positivity

结局指标

主要结局

progression free survival

时间窗: 5 years

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

e_dann

Prof Eldad Dann

Rambam Health Care Campus

研究点 (1)

Loading locations...

相似试验